Clinical responses to lenalidomide therapy. Discoid lupus erythematosus (patient number 12) on upper back before (A) and after 3 months of lenalidomide therapy (5 mg/d) (B). Resolution of the erythema with persistent residual hypopigmentation and some degree of scarring, already existing at baseline from previous cutaneous involvement. Widespread discoid lupus erythematosus (DLE) (patient number 9) involving nose and malar area before (C) and after three months of therapy (D) resulting in a partial improvement of the erythema and increased hypopigmentation. Widespread subacute cutaneous lupus erythematosus (SCLE) (patient number 6) involving face and V-neck area before (E), and complete resolution after 6 weeks of lenalidomide therapy (F). All patients concerned gave their written consent for the publication of the images.
Cortés-Hernández et al. Arthritis Research & Therapy 2012 14:R265 doi:10.1186/ar4111